☆SR ONE CAPITAL MANAGEMENT, LP
Quality Q
0.521
AUM ($M)
1,039
Positions
15
Turnover
0.36
Top-10 wt
95%
Herfindahl
0.140
History (qtrs)
6
Excess Return
—
AI Eval Run AI Eval
Holdings · 17 positions · portfolio value $1,039M
| Ticker | Name | Activity | Security Type | Weight | Δ Weight | Value ($M) | Shares | Δ Shares | Qtrs Held | Excess Return |
|---|---|---|---|---|---|---|---|---|---|---|
| ☆MANE funds › | Veradermics, Inc. | HOLD | — | 28.4% | +11.9% | 295.3 | 2,401,868 | +0 | 2 | — |
| ☆ZBIO funds › | Zenas BioPharma, Inc | HOLD | — | 12.3% | +1.5% | 127.9 | 5,037,854 | +0 | 5 | — |
| ☆CRSP funds › | CRISPR Therapeutics AG | HOLD | — | 10.7% | +0.1% | 111.2 | 2,038,763 | +0 | 5 | — |
| ☆AVLN funds › | Avalyn Pharma, Inc | NEW | — | 10.5% | +10.5% | 108.9 | 3,308,649 | +3,308,649 | 1 | — |
| ☆DSGN funds › | Design Therapeutics, Inc. | HOLD | — | 9.1% | +1.5% | 94.4 | 6,526,476 | +0 | 5 | — |
| ☆ODTX funds › | Odyssey Therapeutics, Inc. | NEW | — | 6.8% | +6.8% | 71.0 | 3,794,883 | +3,794,883 | 1 | — |
| ☆ALMS funds › | Alumis Inc. | HOLD | — | 5.3% | +0.6% | 55.2 | 1,959,896 | +0 | 5 | — |
| ☆ORIC funds › | ORIC Pharmaceuticals, Inc. | ADD | — | 4.8% | -1.6% | 50.0 | 4,615,384 | +100,455 | 5 | — |
| ☆MLYS funds › | Mineralys Therapeutics Inc. | HOLD | — | 4.1% | -0.6% | 42.2 | 1,563,966 | +0 | 5 | — |
| ☆SPRY funds › | ARS Pharmaceuticals, Inc. | HOLD | — | 3.1% | -0.4% | 32.1 | 4,012,903 | +0 | 5 | — |
| ☆MOBI funds › | Mobia Medical, Inc | NEW | — | 2.6% | +2.6% | 26.6 | 1,986,072 | +1,986,072 | 1 | — |
| ☆CUSIP:65487U108 funds › | Nkarta, Inc. | HOLD | — | 0.9% | +0.1% | 9.4 | 3,333,333 | +0 | 5 | — |
| ☆OCS funds › | Oculis Holding AG | HOLD | — | 0.9% | -1.0% | 8.9 | 641,022 | +0 | 5 | — |
| ☆RARE funds › | Ultragenyx Pharmaceutical Inc. | HOLD | — | 0.4% | +0.1% | 4.6 | 137,753 | +0 | 3 | — |
| ☆CUSIP:29286M105 funds › | enGene Holdings Inc. | HOLD | — | 0.1% | -0.4% | 1.3 | 747,750 | +0 | 5 | — |
| ☆CUSIP:03940C100 funds › | Arcellx, Inc. | EXIT | — | 0.0% | -29.4% | 0.0 | 0 | -2,346,630 | 0 | — |
| ☆ORKA funds › | Oruka Therapeutics, Inc | EXIT | — | 0.0% | -2.3% | 0.0 | 0 | -430,330 | 0 | — |
Point-in-time history
| Period | AUM ($M) | Positions | Turnover | Top-10 wt | Herfindahl | Quality Q | Skill | Universe |
|---|---|---|---|---|---|---|---|---|
| 2026Q2 | 1,039 | 15 | 0.36 | 95% | 0.140 | 0.521 | — | in |
| 2026Q1 | 915 | 14 | 0.28 | 96% | 0.153 | 0.693 | — | in |
| 2025Q4 | 706 | 13 | 0.16 | 98% | 0.160 | 0.808 | — | in |
| 2025Q3 | 691 | 12 | 0.19 | 98% | 0.168 | 0.785 | — | in |
| 2025Q2 | 461 | 13 | 0.14 | 98% | 0.179 | 0.821 | — | entered |
| 2025Q1 | 389 | 12 | 0.00 | 98% | 0.214 | 0.000 | — | out |
Long US-equity 13F disclosures only · up to 45-day reporting lag · sells = reduce/avoid, not short.
JSON: /api/signals ·
/api/funds ·
/api/status